Key facts
- InxMed’s last known valuation is $306.0M (Aug 2025).
- It has raised $131.6M; the latest was IPO in Aug 2025.
- Notable investors include CMG SDIC Fund, Proxima Ventures (China), Ennovation Ventures, Shaaxi Shantou Capital, Shaanxi Growth Enterprise Guide Fund — 11 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for InxMed
- ·The full record, as it builds
Funding rounds
No funding rounds for InxMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InxMed
Developer of cancer therapeutics designed to treat cancer. The company currently has pharmaceuticals targeting pancreatic, ovarian, gastric and other forms of cancer, enabling healthcare professionals to prescribe more effective treatments to patients.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Employees
- 80
- Website
- inxmed.com/
- Ownership
- In IPO Registration
InxMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InxMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InxMed in its N-PORT filings yet. We sweep new filings monthly.